BRUNO GUEDES BALDI
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina
21 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 21
- Concentration of serum vascular endothelial growth factor D and its correlation with functional and clinical variables in patients with lymphangioleiomyomatosis from a Brazilian reference centre(2017) OLIVEIRA, Martina Rodrigues; AMARAL, Alexandre Franco; ARIMURA, Fabio Eiji; FREITAS, Carolina Salim; KAIRALLA, Ronaldo Adib; CARVALHO, Carlos Roberto Ribeiro de; BALDI, Bruno Guedes
conferenceObject Radiation Pneumonitis in Patients with Interstitial Lung Disease and Lung Cancer: Report of 6 Cases(2020) FREITAS, L. V. de; SERRA, J. P.; NAJAS, G. F.; PRADO, G. F.; KAWASSAKI, A. M.; TAKAGAKI, T. Y.; GABRIELLI, F.; JUNIOR, G. C.; OLIVEIRA, M. R.; KAIRALLA, R. A.; BALDI, B. G.- Diffuse cystic lung disease as the primary tomographic manifestation of bronchiolitis: A case series(2020) OLIVEIRA, M. R. de; DIAS, O. M.; AMARAL, A. F.; NASCIMENTO, E. C. T. do; WANDERLEY, M.; CARVALHO, C. R. R.; BALDI, B. G.
conferenceObject Primary Lung Fibrous Histiocytoma Presenting as Diffuse Pulmonary Cystic Disease(2020) MAIA, A. P.; MARTIN, S. R. San; BRIDI, G. P.; BEDER, T. N.; COLARES, P. F.; HOLZ, I. M.; SERRA, J. P.; NASCIMENTO, E. C. T.; LIMA, L. G. C. A.; AMARAL, A. F.; OLIVEIRA, M. R.; BALDI, B. G.; KAIRALLA, R. A.- Desaturation-distance ratio during field exercise test in lymphangioleiomyomatosis: a cross-sectional study(2021) QUEIROZ, Douglas Silva; SILVA, Cibele Cristine Berto Marques Da; AMARAL, Alexandre Franco; OLIVEIRA, Martina Rodrigues; MORIYA, Henrique Takachi; CARVALHO, Carlos R. R.; BALDI, Bruno Guedes; CARVALHO, Celso R. F.
- Physical activity levels in women with lymphangioleiomyomatosis(2020) QUEIROZ, Douglas Silva; OLIVEIRA, Martina R.; AMARAL, Alexandre F.; SILVA, Cibele C. B. Marques Da; BALDI, Bruno G.; SALGE, Joao M.; CARVALHO, Carlos R. R.; CARVALHO, Celso R. F.
- Idiopathic pulmonary fibrosis can be a transient diagnosis(2016) OLIVEIRA, Martina Rodrigues de; PEREIRA, Daniel Antunes Silva; DIAS, Olivia Meira; KAIRALLA, Ronaldo Adib; CARVALHO, Carlos Roberto Ribeiro; BALDI, Bruno Guedes
- Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre(2017) BALDI, Bruno Guedes; SAMANO, Marcos Naoyuki; CAMPOS, Silvia Vidal; OLIVEIRA, Martina Rodrigues de; AFONSO JUNIOR, Jose Eduardo; CARRARO, Rafael Medeiros; TEIXEIRA, Ricardo Henrique Oliveira Braga; MINGUINI, Isabela Pasqualini; BURLINA, Roni; PATO, Eduardo Zinoni Silva; CARVALHO, Carlos Roberto Ribeiro; COSTA, Andre NathanLung transplantation (LT) is the standard of care for patients with advanced lung diseases, including lymphangioleiomyomatosis (LAM). LAM accounts for only 1% of all LTs performed in the international registry. As a result, the global experience, including the use of mechanistic target of rapamycin (mTOR) inhibitors before and after LT in LAM, is still limited. We conducted a retrospective review of all LAM patients who underwent LT at our centre between 2003 and 2016. Pre- and post-transplant data were assessed. Eleven women with LAM underwent LT, representing 3.3% of all procedures. Ten (91%) patients underwent double-LT. The mean age at diagnosis was 39 +/- 6 years and the mean FEV1 before LT was 28 +/- 14%. Only one patient underwent pleurodesis for recurrent pneumothorax. Pulmonary hypertension was confirmed in 3 (27%) patients. Four (36%) patients received sirolimus preoperatively; three of them received it until the day of LT, and there was no occurrence of bronchial anastomotic dehiscence after the procedure. Four patients (36%) received mTOR inhibitors post-transplant. The median follow-up from LT was 44 months. There were 3 deaths (27%) during the study and survival probabilities at 1, 3, and 5 years after LT were, 90, 90, and 77%, respectively. This data reinforces the role of LT for LAM patients with end-stage disease. The use of sirolimus seems to be safe before LT and the occurrence of complications after LT, including those LAM-related, should be continuously monitored.
- COVID-19 and lymphangioleiomyomatosis: Experience at a reference center and the potential impact of the use ofmTORinhibitors(2020) BALDI, Bruno Guedes; AMARAL, Alexandre Franco; COLARES, Phillipe de Figueiredo Braga; KAIRALLA, Ronaldo Adib; OLIVEIRA, Martina Rodrigues de; CARVALHO, Carlos Roberto Ribeiro
conferenceObject Antisynthetase Syndrome Interstitial Lung Disease Acute Exacerbation Due to Bacterial Infection: Case Report(2018) SOUZA, H. S. Pinto; ASSUNCAO, G. L.; OLIVEIRA FILHO, J. R. Bandeira de; VARGAS, L. Paez; COSTA, F. M. da; OLIVEIRA, M. Rodrigues de; ARIMURA, F. E.; AMARAL, A. F.; BALDI, B. G.; KAIRALLA, R. A.
- «
- 1 (current)
- 2
- 3
- »